Science Explorer Interactive view Map
Nonprofit · Raleigh · United States

North Carolina GlaxoSmithKline Foundation

ncgskfoundation.orgROR OpenAlex
Research works
16
▼ 60% vs 2013–17
Citations
449
28.1 per fractional work
Top-10% rate
21.7%
record average 16.5%
Open access
50%
world 28%

Not ranked overall: North Carolina GlaxoSmithKline Foundation is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 2.09× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 18.37× its world share, 0 worksImmunology and Micro…Pharmacology, Toxicology and Pharmaceutics: 29.40× its world share, 0 worksPharmacology, Toxico…Computer Science: 1.33× its world share, 0 worksComputer ScienceMedicine: 2.48× its world share, 1 worksMedicineEconomics, Econometrics and Finance: 0.88× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 29.4×. Every wedge is a field page.

Which research topics does North Carolina GlaxoSmithKline Foundation publish most on?

By volume in 2022–2025: Immunodeficiency and Autoimmune Disorders, Biomedical Text Mining and Ontologies, Pharmacovigilance and Adverse Drug Reactions and Topic Modeling.

Immunodeficiency and Aut…0Immunodeficiency and Autoimmune Disorders: 0 fractional worksBiomedical Text Mining a…0Biomedical Text Mining and Ontologies: 0 fractional worksPharmacovigilance and Ad…0Pharmacovigilance and Adverse Drug Reactions: 0 fractional worksTopic Modeling0Topic Modeling: 0 fractional worksCOVID-19 Clinical Resear…0COVID-19 Clinical Research Studies: 0 fractional worksSARS-CoV-2 and COVID-19 …0SARS-CoV-2 and COVID-19 Research: 0 fractional worksT-cell and B-cell Immunology: 0 fractional worksRadiopharmaceutical Chemistry and Applications: 0 fractional worksMonoclonal and Polyclonal Antibodies Research: 0 fractional worksPregnancy and Medication Impact: 0 fractional works
ImmunologyMolecular BiologyToxicologyArtificial Intelligence3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Immunodeficiency and Autoimmune Disorders Immunology 0 works
  2. 2 Biomedical Text Mining and Ontologies Molecular Biology 0 works
  3. 3 Pharmacovigilance and Adverse Drug Reactions Toxicology 0 works
  4. 4 Topic Modeling Artificial Intelligence 0 works
  5. 5 COVID-19 Clinical Research Studies Infectious Diseases 0 works
  6. 6 SARS-CoV-2 and COVID-19 Research Infectious Diseases 0 works
  7. 7 T-cell and B-cell Immunology Immunology 0 works
  8. 8 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 0 works
  9. 9 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  10. 10 Pregnancy and Medication Impact Public Health, Environmental and Occupational Health 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available50.4%not open49.6%

World: 28% of research is openly available.

with international co-authors37.7%domestic only62.3%

World: 19% is written across borders.

How has North Carolina GlaxoSmithKline Foundation's research output changed?

Output in 2018–2022 was 60% lower than in 2013–2017.

2005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Raleigh

All research institutions in Raleigh

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.